Institutes
Refine
Year of publication
Document Type
- Article (1820)
- Doctoral Thesis (444)
- Preprint (158)
- Conference Proceeding (108)
- Review (32)
- Book (17)
- Part of Periodical (12)
- Contribution to a Periodical (9)
- Part of a Book (7)
- Report (3)
Is part of the Bibliography
- no (2612)
Keywords
- COVID-19 (45)
- SARS-CoV-2 (37)
- inflammation (32)
- Epilepsy (19)
- Video (19)
- Inflammation (17)
- prostate cancer (17)
- ADHD (13)
- Cancer (12)
- autophagy (12)
Institute
- Medizin (2612)
- Biowissenschaften (32)
- Biochemie und Chemie (30)
- Biochemie, Chemie und Pharmazie (29)
- Georg-Speyer-Haus (25)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (19)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (19)
- Präsidium (17)
- Frankfurt Institute for Advanced Studies (FIAS) (16)
- Ernst Strüngmann Institut (12)
Wissenschaftsbasierte und verständliche Gesundheitsinformationen sind ein Kernelement der Evidenzbasierten Medizin und von Public Health. Ziel ist es, informierte Entscheidungen zu ermöglichen, die auf realistischen Einschätzungen von Gesundheitsrisiken sowie von Nutzen und Schaden möglicher Interventionen beruhen. In Deutschland wurden während der COVID-19-Pandemie die Standards für eine evidenzbasierte Risikokommunikation wenig beachtet. Häufig war die öffentliche Berichterstattung einseitig, unvollständig und missverständlich. Bedrohungsszenarien haben emotionalen Stress und unnötige Angst ausgelöst. Eine systematische und umfassende Aufarbeitung der Pandemiemaßnahmen ist auch in Deutschland dringlich geboten. Dabei müsste eine kritisch-konstruktive Analyse der medialen Risikokommunikation von Expert*innen, Politiker*innen und Medien ein zentrales Element der Aufarbeitung sein. Die Ergebnisse sollen helfen, aus der vergangenen Pandemie zu lernen, um für künftige Krisen besser vorbereitet zu sein.
Abstract
The co-occurrence of insulin resistance (IR)-related metabolic conditions with neuropsychiatric disorders is a complex public health challenge. Evidence of the genetic links between these phenotypes is emerging, but little is currently known about the genomic regions and biological functions that are involved. To address this, we performed Local Analysis of [co]Variant Association (LAVA) using large-scale (N=9,725-933,970) genome-wide association studies (GWASs) results for three IR-related conditions (type 2 diabetes mellitus, obesity, and metabolic syndrome) and nine neuropsychiatric disorders. Subsequently, positional and expression quantitative trait locus (eQTL)-based gene mapping and downstream functional genomic analyses were performed on the significant loci. Patterns of negative and positive local genetic correlations (|rg|=0.21-1, pFDR<0.05) were identified at 109 unique genomic regions across all phenotype pairs. Local correlations emerged even in the absence of global genetic correlations between IR-related conditions and Alzheimer’s disease, bipolar disorder, and Tourette’s syndrome. Genes mapped to the correlated regions showed enrichment in biological pathways integral to immune-inflammatory function, vesicle trafficking, insulin signalling, oxygen transport, and lipid metabolism. Colocalisation analyses further prioritised 10 genetically correlated regions for likely harbouring shared causal variants, displaying high deleterious or regulatory potential. These variants were found within or in close proximity to genes, such as SLC39A8 and HLA-DRB1, that can be targeted by supplements and already known drugs, including omega-3/6 fatty acids, immunomodulatory, antihypertensive, and cholesterol-lowering drugs. Overall, our findings underscore the complex genetic landscape of IR-neuropsychiatric multimorbidity, advocating for an integrated disease model and offering novel insights for research and treatment strategies in this domain.
Highlights
Local genetic correlations found even in the absence of global correlations.
Both positive and negative local correlations found for IR-neuropsychiatric pairs.
Enrichment for immune, and insulin signalling pathways, among others.
Pinpointed shared likely causal variants within 10 genomic regions.
Identified therapeutic targets, e.g., SLC39A8 and HLA-DRB1, for drug repurposing.